Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study - Summary - MDSpire
Advertisement
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
To evaluate the potential impact of COVID-19 on patient outcomes, including progression-free survival and overall survival, with teclistamab in the MajesTEC-1 study.
Key Findings:
48 patients (29.1%) experienced COVID-19 infections, with 18 deaths (10.9%) attributed to COVID-19, indicating a significant impact on this vulnerable population.
Teclistamab treatment was interrupted in 29 of the 48 COVID-19 cases, reflecting the challenges in managing treatment during the pandemic.
Patients who were unvaccinated had a higher risk of COVID-19 infection and earlier mortality compared to vaccinated patients, underscoring the importance of vaccination.
Median progression-free survival (PFS) was 11.3 months, and overall survival (OS) was 21.9 months; outcomes improved when censoring for COVID-19 deaths, suggesting the need for careful interpretation of survival data.
Interpretation:
The study highlights the vulnerability of multiple myeloma patients to COVID-19 and emphasizes that vaccination significantly improved outcomes during teclistamab treatment, suggesting a need for prioritizing vaccination in this population.
Limitations:
The analysis is post hoc and may be subject to biases, particularly in patient selection and data interpretation.
Variability in infection management protocols across institutions may affect the generalizability of the findings.
Conclusion:
COVID-19 significantly affected outcomes in patients with relapsed/refractory multiple myeloma receiving teclistamab, underscoring the importance of vaccination and infection management strategies.
by Niels W. C. J. van de Donk, Nizar Bahlis, Luciano J. Costa, María-Victoria Mateos, Ajay K. Nooka, Aurore Perrot, Alfred L. Garfall, Pragya Thaman, Keqin Qi, Clarissa Uhlar, Katherine Chastain, Margaret Doyle, Saad Z. Usmani
